KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Payables (2018 - 2025)

Progyny (PGNY) has disclosed Payables for 8 consecutive years, with $124.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables changed N/A to $124.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $124.1 million, a N/A change, with the full-year FY2025 number at $124.1 million, changed N/A from a year prior.
  • Payables was $124.1 million for Q4 2025 at Progyny, up from $123.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $151.7 million in Q2 2024 to a low of $54.7 million in Q2 2021.
  • A 5-year average of $110.5 million and a median of $124.1 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: soared 87.94% in 2022, then fell 10.61% in 2024.
  • Progyny's Payables stood at $61.4 million in 2021, then soared by 77.99% to $109.3 million in 2022, then grew by 14.77% to $125.4 million in 2023, then increased by 4.02% to $130.5 million in 2024, then fell by 4.9% to $124.1 million in 2025.
  • Per Business Quant, the three most recent readings for PGNY's Payables are $124.1 million (Q4 2025), $123.1 million (Q3 2025), and $140.5 million (Q2 2025).